New cancer clinical trial: DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer

Published on: November 30, 2018 at 12:00PM
Conditions:   Esophagogastric Cancer;   Biliary Tract Cancer;   GastroEsophageal Cancer;   Hepatobiliary Neoplasm
Interventions:   Drug: DKN-01;   Drug: Paclitaxel;   Drug: Atezolizumab
Sponsors:   European Organisation for Research and Treatment of Cancer - EORTC;   Hoffmann-La Roche;   Leap Therapeutics, Inc.
Not yet recruiting
https://ift.tt/2QwO0Is